Biblio Discovery — Demo Discovery Service

112 hasil

Menampilkan 1–20 · 0,62 detik · RSS

Jurnal

Blood Neoplasia

Scopus

ISSN 2950-3280 · Elsevier · 112 artikel di indeks

  1. Artikel Jurnal

    Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML

    Jayanshu Jain; Kelly Pugh; Shivani Handa dkk.

    Blood Neoplasia, Vol. 3 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract: This phase 1 study investigated the addition of gemtuzumab ozogamicin (GO) to intensive chemotherapy with cytarabine, daunorubicin, and midostaurin in 21 patients with newly diagnosed (ND) FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML). Four dose levels of GO were…

  2. Artikel Jurnal

    Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response

    Anna Maria Corsale; Mojtaba Shekarkar Azgomi; Emilia Gigliotta dkk.

    Blood Neoplasia, Vol. 3 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract: The progression of multiple myeloma (MM) is characterized by intricate interactions between clonal plasma cells and the bone marrow (BM) microenvironment. In this study, we conducted a comprehensive analysis of BM immune cell composition spanning from premalignant stages to MM, using…

  3. Artikel Jurnal

    Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia

    Yoke Seng Lee; Jonathan D. Good; Noha Awais dkk.

    Blood Neoplasia, Vol. 3 No. 2 · 2026 · Inggris · DOAJ Scopus

    Abstract: Targeted therapies, such as the BCL-2 inhibitor venetoclax, have expanded the treatment options for patients with acute myeloid leukemia (AML), but survival remains poor because of drug resistance and disease relapse. We found that the translation initiation factor EIF4A1, which unwinds…

  4. Artikel Jurnal

    Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease

    Christoph Weigel; Haley L. Klimaszewski; Fode Tounkara dkk.

    Blood Neoplasia, Vol. 3 No. 2 · 2026 · Inggris · DOAJ Scopus

    Abstract: Epstein-Barr virus (EBV)–associated primary central nervous system lymphoproliferative diseases (EBV+PCNSL) are aggressive conditions with poor prognoses. We previously reported durable responses in patients with PCNSL who were treated with the antivirals ganciclovir and azidothymidine…

  5. Artikel Jurnal

    Excess body weight at diagnosis is associated with inferior ALL outcomes in male adolescents in the ALL-BFM 2000 study

    Martin Zimmermann; Christian Denzer; Anja Möricke dkk.

    Blood Neoplasia, Vol. 3 No. 4 · 2026 · Inggris · DOAJ Scopus

    Abstract: Body weight at diagnosis may influence outcomes in childhood acute lymphoblastic leukemia (ALL), although current evidence remains conflicting. Both, underweight and overweight/obesity at diagnosis can negatively affect outcomes. Here, we present data from the ALL-BFM 2000 trial on excess…

  6. Artikel Jurnal

    Single-cell sequencing reveals transcriptional and immunogenetic diversity in stereotyped chronic lymphocytic leukemia

    Blaž Oder; Leily Rabbani; Teresa del Peso Santos dkk.

    Blood Neoplasia, Vol. 3 No. 4 · 2026 · Inggris · DOAJ Scopus

    Abstract: Chronic lymphocytic leukemia (CLL) comprises immunogenetically defined stereotyped subsets of patients with distinct B-cell receptor (BcR) immunoglobulin features and clinical trajectories, yet the molecular pathways underlying subset-specific differences remain incompletely…

  7. Artikel Jurnal

    IMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable

    Sarah A. Bird; Marco P. Licciardello; Ananya Sukhtankar dkk.

    Blood Neoplasia, Vol. 3 No. 4 · 2026 · Inggris · DOAJ Scopus

    Abstract: Immunomodulatory drugs (IMiDs) are a cornerstone of multiple myeloma treatment, and newer cereblon E3 ligase modulatory drugs (CELMoDs) are in clinical trials. However, a major barrier to improving patient outcomes is the inevitable development of resistance to these agents. To explore…

  8. Artikel Jurnal

    CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

    Yesid Alvarado; Jayastu Senapati; Tapan M. Kadia dkk.

    Blood Neoplasia, Vol. 3 No. 4 · 2026 · Inggris · DOAJ Scopus

    Abstract: Outcomes of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and those with myelodysplastic syndrome (MDS) with increased blasts (IB) who progress after therapy with hypomethylating agents (HMA) are dismal, especially when without targetable genetic aberrations. In…

  9. Artikel Jurnal

    Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma

    Lorenzo Iovino; Ningxin Ma; Mohamed A. Kharfan-Dabaja dkk.

    Blood Neoplasia, Vol. 3 No. 3 · 2026 · Inggris · DOAJ Scopus

    Abstract: In the era of chimeric antigen receptor (CAR) T-cell therapy, autologous stem cell transplant (ASCT) for diffuse large B-cell lymphoma (DLBCL) is preferentially offered to patients with late relapse (>12 months) who achieve complete or partial response (CR or PR, respectively) to salvage…

  10. Artikel Jurnal

    From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models

    Tamara C. A. I. Verbeek; Kirsten S. Vrenken; Susan T. C. J. M. Arentsen-Peters dkk.

    Blood Neoplasia, Vol. 3 No. 3 · 2026 · Inggris · DOAJ Scopus

    Abstract: Despite recent advances in clinical outcome for infants diagnosed with KMT2A-rearranged acute lymphoblastic leukemia (ALL), the development of more effective and less toxic induction therapies remains desirable. As this requires multidrug regimens, the identification of synergizing agents…

  11. Artikel Jurnal

    Favezelimab plus pembrolizumab for anti–PD-1–refractory classic Hodgkin lymphoma: an open-label phase 1/2 study

    John Timmerman; David Lavie; Nathalie A. Johnson dkk.

    Blood Neoplasia, Vol. 3 No. 4 · 2026 · Inggris · DOAJ Scopus

    Abstract: The MK-4280-003 study evaluated favezelimab plus pembrolizumab in hematologic malignancies. We report results for anti–programmed cell death protein 1 (PD-1)–refractory classic Hodgkin lymphoma (cHL; cohort 2). Participants in the safety lead-in had relapsed or refractory (R/R) cHL…

  12. Artikel Jurnal

    Hypomethylating agents–venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT

    Diana T. Samuels; Brian J. Ball; Ni-Chun Tsai dkk.

    Blood Neoplasia, Vol. 3 No. 3 · 2026 · Inggris · DOAJ Scopus

    Abstract: Relapse after allogeneic hematopoietic cell transplantation (alloHCT) remains a challenge for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and salvage therapy in this setting is not standardized. Given the efficacy of hypomethylating agents and venetoclax…

  13. Artikel Jurnal

    Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis

    Hamza Celik; Brittney Wass; Nina Zolotarjova dkk.

    Blood Neoplasia, Vol. 3 No. 2 · 2026 · Inggris · DOAJ Scopus

    Abstract: Four Janus kinase inhibitors (JAKinibs), ruxolitinib, fedratinib, pacritinib, and momelotinib, are indicated for myelofibrosis. All inhibit JAK2, but effects on additional kinases vary markedly, shaping their specific clinical pharmacology. Published comparative inhibitory profiles and…